CoChat

Pamrevlumab for the treatment of idiopathic pulmonary fibrosis

Sgalla, Giacomo, Franciosa, Claudia, Simonetti, Jacopo, Richeldi, Luca · 2020 · Expert Opinion on Investigational Drugs

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

INTRODUCTION: The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow down but do not halt IPF progression. As such, in the last few years several agents with specific molecular targets have been investigated to find a cure forIPF. Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for IPF and has advanced to phase 3 clinical trials. AREAS COVERED: The authors offer a backdrop to the current IPF treatment market and describe the chemistry, pharmacokinetics and pharmacodynamics of pamrevlumab. They summarize the preclinical and early clinical evidence on pamrevlumab and propose ways of progressing this agent further as a potential IPF treatment. EXPERT OPINION: Pamrevlumab was effective and safe in patients in a placebo-controlled phase 2 trial, demonstrating its potential to become an alternative therapeutic option for IPF; however, the feasibility of intravenous administration in clinical practice may be a hurdle to its use as a first-line treatment. Further studies are necessary to assess its effects when administered with pirfenidone or nintedanib and this could open up a new era of combined therapeutic approaches for IPF.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2020.1773790

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 40 · Cited by 59

Research works printed but not linked: 4

  1. Fisher M, 2017, J Manag Care Spec Pharm, 23, S17
  2. 10.1016/S2213-2600(19)30262-0. · DOI · Paper page
  3. Gorina E, 2018, Am J Respir Crit Care Med, 8, 25
  4. Flaherty KR, 2019, N Engl J Med, 382, 779

Metadata

Authors
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L.
Affiliations
  • Agostino Gemelli University Polyclinic (IT)
  • Università Cattolica del Sacro Cuore (IT)
Corresponding author
Sgalla, Giacomo
Venue
Expert Opinion on Investigational Drugs
Published
2020-06-07
Volume
29
Issue
8
Pages
771-777
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W3027885648
Cited by
59
References
40
Citations by year
2026: 2 · 2025: 6 · 2024: 11 · 2023: 19 · 2022: 10 · 2021: 8 · 2020: 3
FWCI
5.62
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
idiopathic pulmonary fibrosis, connective tissue growth factor, monoclonal antibodies, pirfenidone, nintedanib, combination therapy, pharmacokinetics, pharmacodynamics, intravenous administration, antifibrotic therapy
MeSH terms
Animals, Humans, Indoles, Pyridones, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis, Connective Tissue Growth Factor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1080/13543784.2020.1773790
The paper
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020). Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2020.1773790

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.